AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny
In this column for Law360, Chuck Slemp analyzes how a Virginia investigation into insulin manufacturers and pharmacy benefit managers reflects a broader national trend of state AGs targeting drug pricing practices using consumer protection and antitrust laws to tackle opaque pricing structures and drive healthcare affordability.


